platelet: be given to cancer patients

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents blood cell
Weight: 0.64
, particle
Weight: 0.63
, white blood cell
Weight: 0.55
, blood transfusion
Weight: 0.55
, tissue
Weight: 0.54
Siblings red blood cell
Weight: 0.37
, leukocyte
Weight: 0.35
, neutrophil
Weight: 0.35

Related properties

Property Similarity
be given to cancer patients 1.00
be high in cancer patients 0.96
be low in cancer patients 0.95
be given to leukemia patients 0.95
increase with cancer 0.84
be low in kidney disease 0.80
be low in leukemia 0.79
be low with liver disease 0.79
be low during chemo 0.78
be decreased in liver disease 0.76

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Plausibility inference from child typicality

0.63
Rule weight: 0.66
Evidence weight: 0.95
Similarity weight: 1.00
Evidence: 0.94
Plausible(blood transfusion, be given to cancer patients) ⋁
Evidence: 0.92
¬ Typical(platelet, be given to cancer patients)

Plausibility inheritance from parent to child

0.08
Rule weight: 0.09
Evidence weight: 0.83
Similarity weight: 1.00
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.94
¬ Plausible(blood transfusion, be given to cancer patients)

Remarkability exclusitivity betweem a parent and a child

0.44
Rule weight: 0.58
Evidence weight: 0.77
Similarity weight: 1.00
Evidence: 0.45
¬ Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.53
¬ Remarkable(blood transfusion, be given to cancer patients)

Remarkability exclusitivity between siblings

0.09
Rule weight: 0.13
Evidence weight: 0.82
Similarity weight: 0.79
Evidence: 0.45
¬ Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.40
¬ Remarkable(neutrophil, be low in leukemia)

Remarkability from parent implausibility

0.41
Rule weight: 0.42
Evidence weight: 0.97
Similarity weight: 1.00
Evidence: 0.94
Plausible(blood transfusion, be given to cancer patients) ⋁
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.82
¬ Plausible(platelet, be given to cancer patients)

Remarkability from sibling implausibility

0.44
Rule weight: 0.60
Evidence weight: 0.92
Similarity weight: 0.79
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.40
Remarkable(neutrophil, be low in leukemia) ⋁
Evidence: 0.73
¬ Plausible(neutrophil, be low in leukemia)

Salient implies Plausible

0.24
Rule weight: 0.28
Evidence weight: 0.85
Similarity weight: 1.00
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.82
¬ Salient(platelet, be given to cancer patients)

Similarity expansion

0.75
Rule weight: 0.85
Evidence weight: 0.93
Similarity weight: 0.95
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.87
¬ Typical(platelet, be given to leukemia patients)
0.70
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.95
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.76
¬ Plausible(platelet, be given to leukemia patients)
0.70
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.95
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.75
¬ Salient(platelet, be given to leukemia patients)
0.64
Rule weight: 0.85
Evidence weight: 0.93
Similarity weight: 0.80
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.82
¬ Typical(platelet, be low in kidney disease)
0.64
Rule weight: 0.85
Evidence weight: 0.94
Similarity weight: 0.79
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.71
¬ Typical(platelet, be low with liver disease)
0.63
Rule weight: 0.85
Evidence weight: 0.93
Similarity weight: 0.79
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.85
¬ Typical(platelet, be low in leukemia)
0.61
Rule weight: 0.85
Evidence weight: 0.95
Similarity weight: 0.76
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.61
¬ Typical(platelet, be decreased in liver disease)
0.61
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.95
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.43
¬ Remarkable(platelet, be given to leukemia patients)
0.60
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.79
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.67
¬ Plausible(platelet, be low with liver disease)
0.59
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.80
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.78
¬ Plausible(platelet, be low in kidney disease)
0.59
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.79
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.72
¬ Salient(platelet, be low in leukemia)
0.59
Rule weight: 0.85
Evidence weight: 0.87
Similarity weight: 0.79
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.74
¬ Plausible(platelet, be low in leukemia)
0.58
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.79
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.75
¬ Salient(platelet, be low with liver disease)
0.58
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.80
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.86
¬ Salient(platelet, be low in kidney disease)
0.57
Rule weight: 0.85
Evidence weight: 0.89
Similarity weight: 0.76
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.64
¬ Plausible(platelet, be decreased in liver disease)
0.56
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.76
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.78
¬ Salient(platelet, be decreased in liver disease)
0.52
Rule weight: 0.85
Evidence weight: 0.76
Similarity weight: 0.79
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.43
¬ Remarkable(platelet, be low in leukemia)
0.43
Rule weight: 0.85
Evidence weight: 0.64
Similarity weight: 0.79
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.65
¬ Remarkable(platelet, be low with liver disease)
0.43
Rule weight: 0.85
Evidence weight: 0.63
Similarity weight: 0.80
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.67
¬ Remarkable(platelet, be low in kidney disease)
0.37
Rule weight: 0.85
Evidence weight: 0.57
Similarity weight: 0.76
Evidence: 0.45
Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.77
¬ Remarkable(platelet, be decreased in liver disease)

Typical and Remarkable implies Salient

0.13
Rule weight: 0.14
Evidence weight: 0.93
Similarity weight: 1.00
Evidence: 0.82
Salient(platelet, be given to cancer patients) ⋁
Evidence: 0.92
¬ Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.45
¬ Remarkable(platelet, be given to cancer patients)

Typical implies Plausible

0.40
Rule weight: 0.48
Evidence weight: 0.84
Similarity weight: 1.00
Evidence: 0.82
Plausible(platelet, be given to cancer patients) ⋁
Evidence: 0.92
¬ Typical(platelet, be given to cancer patients)

Typicality and Rermarkability incompatibility between a parent and a child

0.29
Rule weight: 0.51
Evidence weight: 0.56
Similarity weight: 1.00
Evidence: 0.45
¬ Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.99
¬ Typical(blood transfusion, be given to cancer patients)

Typicality and Rermarkability incompatibility between siblings

0.07
Rule weight: 0.14
Evidence weight: 0.62
Similarity weight: 0.79
Evidence: 0.45
¬ Remarkable(platelet, be given to cancer patients) ⋁
Evidence: 0.86
¬ Typical(neutrophil, be low in leukemia)

Typicality inheritance from parent to child

0.44
Rule weight: 0.48
Evidence weight: 0.92
Similarity weight: 1.00
Evidence: 0.92
Typical(platelet, be given to cancer patients) ⋁
Evidence: 0.99
¬ Typical(blood transfusion, be given to cancer patients)